NCT06544655 2026-04-17
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Active not recruiting
Clinical Trials
81 trialsNCT06324357 2026-04-15
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
Phase 1/2 Recruiting
NCT05489211 2026-03-19
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
Phase 2 Recruiting
NCT05464030 2026-03-18
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
EMD Serono
Phase 1 Recruiting
NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
NCT04854668 2026-01-30
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Active not recruiting
NCT03869892 2025-12-22
SOLSTICE
Servier
Phase 3 Active not recruiting
NCT02955940 2025-12-17
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Incyte Corporation
Phase 2 Active not recruiting
NCT06328738 2025-11-19
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
Enliven Therapeutics
Phase 1 Active not recruiting
NCT07233850 2025-11-18
A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 2 Not yet recruiting
NCT05382442 2025-10-14
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
Akeso
Phase 2 Active not recruiting
NCT05609370 2025-10-02
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
BeiGene
Phase 1/2 Active not recruiting
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT04607421 2025-08-14
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
Phase 3 Active not recruiting
NCT07025239 2025-06-17
QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT05704985 2025-05-29
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Phase 1 Active not recruiting
NCT05141721 2025-05-16
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Seattle Project Corporation
Phase 2/3 Active not recruiting
NCT06963502 2025-05-09
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT05093907 2025-03-10
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer
BeyondBio Inc.
Phase 1/2 Recruiting
NCT03169777 2025-02-21
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT06825624 2025-02-13
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT02780700 2025-02-03
Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]
Boehringer Ingelheim
Phase 2 Terminated
NCT03563157 2024-12-11
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT04456699 2024-10-29
LYNK-003
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06493760 2024-09-19
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2 Recruiting
NCT02743221 2024-08-20
TASCO1
Servier
Phase 2 Completed
NCT06547385 2024-08-09
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer
Ono Pharmaceutical Co. Ltd
Phase 1 Active not recruiting
NCT02291289 2024-05-06
MODUL
Hoffmann-La Roche
Phase 2 Completed
NCT01776307 2023-11-15
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Sumitomo Pharma America, Inc.
Phase 2 Completed
NCT05799820 2023-05-25
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
Qilu Pharmaceutical Co., Ltd.
Phase 2 Unknown
NCT05091528 2022-08-18
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Silverback Therapeutics
Phase 1/2 Terminated
NCT00069121 2020-03-06
A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT04097444 2019-10-31
QUATTRO-II
Chugai Pharmaceutical
Phase 2 Unknown
NCT03645876 2019-05-10
SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Terminated
NCT02083653 2019-04-16
Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
Symphogen A/S
Phase 2 Completed
NCT01588990 2019-01-22
ASCENT
Hoffmann-La Roche
Phase 4 Completed
NCT00551213 2018-08-24
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01705002 2018-07-10
Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.
Lipomedix Pharmaceuticals Inc.
Phase 1 Completed
NCT01506167 2018-05-14
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
Hoffmann-La Roche
Completed
NCT00642603 2018-03-29
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT00536809 2017-12-18
Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer
GlaxoSmithKline
Phase 1 Completed
NCT01765582 2017-09-18
STEAM
Hoffmann-La Roche
Phase 2 Terminated
NCT01696695 2017-03-23
AXEL
Hoffmann-La Roche
Completed
NCT00399035 2016-12-28
HORIZON II
AstraZeneca
Phase 3 Completed
NCT02210364 2016-12-14
Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).
PharmaMar
Phase 1 Completed
NCT00048126 2016-11-02
A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00048139 2016-11-02
A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00700570 2016-11-02
A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT01493336 2016-11-02
A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours
Hoffmann-La Roche
Phase 1 Completed